1
|
Cui B, Zheng Y, Sun H, Shang H, Du M, Shang Y, Yavuz CT. Catalytic enantioselective intramolecular hydroamination of alkenes using chiral aprotic cyclic urea ligand on manganese (II). Nat Commun 2024; 15:6647. [PMID: 39103345 DOI: 10.1038/s41467-024-50757-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Accepted: 07/18/2024] [Indexed: 08/07/2024] Open
Abstract
Asymmetric catalysis for enantioselective intramolecular hydroamination of alkenes is a critical method in the construction of enantioenriched nitrogen-containing rings, often prevalent in biologically active compounds and natural products. Herein, we demonstrate a facile enantioselective intramolecular hydroamination of alkenes for the synthesis of chiral pyrrolidine, piperidine, and indoline moieties, using a manganese (II) chiral aprotic cyclic urea catalyst. The cyclic ligand hinders the inversion of the N atom of the urea and effectively discriminate between the enantiomers of substrates. High-resolution mass spectrometry, deuterium labeling experiments, and molecular orbital energy analysis clearly reveal the intermediates and mechanism of the transformation. As a key step, oxygen coordination by chiral aprotic urea presents a robust control over the asymmetric intra-HA reaction through the involvement of a convergent assembly of two vital intermediates (Mn-N and C-Mn-Br), providing access to chiral cyclic amine systems in high yields with excellent enantioselectivity.
Collapse
Affiliation(s)
- Bin Cui
- Manganese Catalysis and Asymmetric Synthesis Laboratory, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, P. R. China
| | - Yuting Zheng
- Manganese Catalysis and Asymmetric Synthesis Laboratory, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, P. R. China
| | - Hui Sun
- Manganese Catalysis and Asymmetric Synthesis Laboratory, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, P. R. China.
| | - Huijian Shang
- Manganese Catalysis and Asymmetric Synthesis Laboratory, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, P. R. China
| | - Man Du
- Manganese Catalysis and Asymmetric Synthesis Laboratory, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, P. R. China
| | - Yuxuan Shang
- Oxide & Organic Nanomaterials for Energy & Environment Laboratory, Physical Science & Engineering (PSE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
| | - Cafer T Yavuz
- Oxide & Organic Nanomaterials for Energy & Environment Laboratory, Physical Science & Engineering (PSE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
| |
Collapse
|
2
|
Krivdin LB. Tritium NMR: A compilation of data and a practical guide. MAGNETIC RESONANCE IN CHEMISTRY : MRC 2023; 61:195-247. [PMID: 36593685 DOI: 10.1002/mrc.5329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 12/22/2022] [Accepted: 12/23/2022] [Indexed: 06/17/2023]
Abstract
The present review is focused on experimental methods and structural applications of tritium NMR. It consists of five parts covering accordingly, introduction, brief overview, early (based on the papers appearing before 2000), more recent (based on the papers appeared in the interim of 2000 to 2015), and recent (based on the papers that appeared after 2015) reports. A special interest in this review is focused on practical aspects of tritium NMR spectroscopy, which is thoroughly illustrated by its numerous applications in chemistry and biochemistry.
Collapse
Affiliation(s)
- Leonid B Krivdin
- A.E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia
| |
Collapse
|
3
|
Némethy Z, Kiss B, Lethbridge N, Chazot P, Hajnik T, Tóth A, Détári L, Schmidt É, Czurkó A, Kostyalik D, Oláh V, Hernádi I, Balázs O, Vizi ES, Ledneczki I, Mahó S, Román V, Lendvai B, Lévay G. Convergent cross-species pro-cognitive effects of RGH-235, a new potent and selective histamine H 3 receptor antagonist/inverse agonist. Eur J Pharmacol 2021; 916:174621. [PMID: 34965389 DOI: 10.1016/j.ejphar.2021.174621] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 10/29/2021] [Accepted: 11/03/2021] [Indexed: 11/30/2022]
Abstract
The histamine H3 receptor is a favourable target for the treatment of cognitive deficits. Here we report the in vitro and in vivo profile of RGH-235, a new potent, selective, and orally active H3 receptor antagonist/inverse agonist developed by Gedeon Richter Plc. Radioligand binding and functional assays were used for in vitro profiling. Procognitive efficacy was investigated in rodent cognitive tests, in models of attention deficit hyperactive disorder (ADHD) and in cognitive tests of high translational value (rat touch screen visual discrimination test, primate fixed-foreperiod visual reaction time task). Results were supported by pharmacokinetic studies, neurotransmitter release, sleep EEG and dipsogenia. RGH-235 displayed high affinity to H3 receptors (Ki = 3.0-9.2 nM, depending on species), without affinity to H1, H2 or H4 receptors and >100 other targets. RGH-235 was an inverse agonist ([35S] GTPγS binding) and antagonist (pERK1/2 ELISA), showing favourable kinetics, inhibition of the imetit-induced dipsogenia and moderate effects on sleep-wake EEG. RGH-235 stimulated neurotransmitter release both in vitro and in vivo. RGH-235 was active in spontaneously hypertensive rats (SHR), generally considered as a model of ADHD, and revealed a robust pro-cognitive profile both in rodent and primate tests (in 0.3-1 mg/kg) and in models of high translational value (e.g. in a rodent touch screen test and in non-human primates). The multiple and convergent procognitive effects of RGH-235 support the view that beneficial cognitive effects can be linked to antagonism/inverse agonism of H3 receptors.
Collapse
Affiliation(s)
- Zsolt Némethy
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary.
| | - Béla Kiss
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | | | - Paul Chazot
- Department of Biosciences, Durham University, Durham, UK
| | - Tünde Hajnik
- Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary
| | - Attila Tóth
- Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary
| | - László Détári
- Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary
| | - Éva Schmidt
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - András Czurkó
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Diána Kostyalik
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Vilmos Oláh
- Department of Experimental Zoology and Neurobiology, Faculty of Sciences, Grastyán Translational Research Center and Szentágothai Research Center, University of Pécs, Pécs, Hungary
| | - István Hernádi
- Department of Experimental Zoology and Neurobiology, Faculty of Sciences, Grastyán Translational Research Center and Szentágothai Research Center, University of Pécs, Pécs, Hungary
| | - Ottilia Balázs
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | | | | | - Sándor Mahó
- Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary
| | - Viktor Román
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - Balázs Lendvai
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| | - György Lévay
- Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary
| |
Collapse
|
4
|
Wang J, Zhu Y, Yang L, Liu H, Zhou T, Xu F, Xu P, Yuan L, Liang L. Early Diagnosis of Cerebral Ischemia Reperfusion Injury and Revelation of Its Regional Development by a H 3R Receptor-Directed Probe. ACS Sens 2021; 6:1330-1338. [PMID: 33653024 DOI: 10.1021/acssensors.0c02667] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
In vivo imaging of cerebral hydrogen peroxide (H2O2) may facilitate early diagnosis of cerebral ischemia reperfusion injury (CIRI) and a revelation of its pathological progression. In this study, we report our rational design of a brain-targeting fluorescent probe using the basis of a pyridazinone scaffold. A structure-activity relationship study reveals that PCAB is the best candidate (Ki = 15.8 nM) for a histamine H3 receptor (H3R), which is highly expressed in neurons of the central nervous system. As a two-photon fluorescent probe, PCAB exhibits a fast, selective reaction toward both extra- and intracellular H2O2 in SH-SY5Y cells under oxygen glucose deprivation and resupply. In vivo fluorescent imaging of a middle cerebral artery occlusion mouse confirms that PCAB is an ultrasensitive probe with potent blood-brain barrier penetration, precise brain targeting, and fast detection of CIRI.
Collapse
Affiliation(s)
- Junda Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Yuanjun Zhu
- Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Lingfei Yang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Hui Liu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Tongliang Zhou
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Fengrong Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Ping Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Lan Yuan
- Medical and Health Analysis Center, Peking University Health Science Center, Beijing 100191, China
| | - Lei Liang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| |
Collapse
|
5
|
Vinogradov MG, Turova OV, Zlotin SG. Catalytic Asymmetric Aza‐Diels‐Alder Reaction: Pivotal Milestones and Recent Applications to Synthesis of Nitrogen‐Containing Heterocycles. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202001307] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Maxim G. Vinogradov
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences 47 Leninsky prosp. 119991 Moscow Russian Federation
| | - Olga V. Turova
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences 47 Leninsky prosp. 119991 Moscow Russian Federation
| | - Sergei G. Zlotin
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences 47 Leninsky prosp. 119991 Moscow Russian Federation
| |
Collapse
|
6
|
Szczepańska K, Kuder KJ, Kieć-Kononowicz K. Dual-targeting Approach on Histamine H 3 and Sigma-1 Receptor Ligands as Promising Pharmacological Tools in the Treatment of CNS-linked Disorders. Curr Med Chem 2021; 28:2974-2995. [PMID: 32767910 DOI: 10.2174/0929867327666200806103144] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 07/16/2020] [Accepted: 07/16/2020] [Indexed: 11/22/2022]
Abstract
With the recent market approval of Pitolisant (Wakix®), the interest in clinical application for novel multifunctional histamine H3 receptor antagonists has clearly increased. Several combinations of different H3R pharmacophores with pharmacophoric elements of other G-protein coupled receptors, transporters, or enzymes have been synthesized by numerous pharmaceutical companies and academic institutions. Since central nervous system disorders are characterized by diverse physiological dysfunctions and deregulations of a complex network of signaling pathways, optimal multipotent drugs should simultaneously and peculiarly modulate selected groups of biological targets. Interestingly, very recent studies have shown that some clinically evaluated histamine H3 receptor antagonists possess a nanomolar affinity for sigma-1 receptor binding sites, suggesting that this property might play a role in their overall efficacy. The sigma-1 receptor, unusual and yet obscure protein, is supposed to be involved in numerous CNS pathologies through neuroprotection and neuroplasticity. These two different biological structures, histamine H3 and sigma-1 receptors, combined, can represent a potential fruitful target for therapeutic developments in tackling numerous human diseases.
Collapse
Affiliation(s)
- Katarzyna Szczepańska
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland
| | - Kamil J Kuder
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland
| | - Katarzyna Kieć-Kononowicz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland
| |
Collapse
|
7
|
Du X, Hou H, Zhao Y, Sheng S, Chen J. Rhodium(III)-Catalyzed Alkynylation of 4-Arylphthalazin-1(2 H
)-one Scaffolds via C-H Bond Activation. European J Org Chem 2020. [DOI: 10.1002/ejoc.201901731] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Xuxin Du
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Hongcen Hou
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Yongli Zhao
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Shouri Sheng
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| | - Junmin Chen
- Key Laboratory of Functional Small Organic Molecules; Ministry of Education and College of Chemistry & Chemical Engineering; Jiangxi Normal University; 330022 Nanchang P. R. China
| |
Collapse
|
8
|
Lima LM, Alves MA, do Amaral DN. Homologation: A Versatile Molecular Modification Strategy to Drug Discovery. Curr Top Med Chem 2019; 19:1734-1750. [PMID: 31393250 DOI: 10.2174/1568026619666190808145235] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 07/04/2019] [Accepted: 07/22/2019] [Indexed: 11/22/2022]
Abstract
Homologation is a concept introduced by Gerhard in 1853 to describe a homologous series in organic chemistry. Since then, the concept has been adapted and used in medicinal chemistry as one of the most important strategies for molecular modification. The homologation types, their influence on physico-chemical properties and molecular conformation are presented and discussed. Its application in lead-identification and lead optimization steps, as well as its impact on pharmacodynamics/pharmacokinetic properties and on protein structure is highlighted from selected examples. • Homologation: definition and types • Homologous series in nature • Comparative physico-chemical and conformational properties • Application in lead-identification and lead-optimization • Impact on pharmacodynamic property • Impact on pharmacokinetic property • Impact on protein structure • Concluding remarks • Acknowledgment • References.
Collapse
Affiliation(s)
- Lídia M Lima
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR;, Laboratorio de Avaliacao e Sintese de Substancias Bioativas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitaria, Rio de Janeiro- RJ, Brazil
| | - Marina A Alves
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR;, Laboratorio de Avaliacao e Sintese de Substancias Bioativas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitaria, Rio de Janeiro- RJ, Brazil
| | - Daniel N do Amaral
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR;, Laboratorio de Avaliacao e Sintese de Substancias Bioativas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitaria, Rio de Janeiro- RJ, Brazil
| |
Collapse
|
9
|
Synthesis and evaluation of histamine H3 receptor ligand based on lactam scaffold as agents for treating neuropathic pain. Bioorg Med Chem Lett 2019; 29:1492-1496. [DOI: 10.1016/j.bmcl.2019.04.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 04/07/2019] [Indexed: 11/30/2022]
|
10
|
Troxler T, Feuerbach D, Zhang X, Yang CR, Lagu B, Perrone M, Wang TL, Briner K, Bock MG, Auberson YP. The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders. ChemMedChem 2019; 14:1238-1247. [PMID: 30957954 DOI: 10.1002/cmdc.201900176] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Indexed: 12/12/2022]
Abstract
Histamine H3 receptor (H3R) inverse agonists that have been in clinical trials for the treatment of excessive sleep disorders, have been plagued with insomnia as a mechanism-based side effect. We focused on the identification of compounds that achieve high receptor occupancy within a short time, followed by rapid disengagement from the receptor, a target profile that could provide therapeutic benefits without the undesired side effect of insomnia. This article describes the optimization work that led to the discovery of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate (18 b, LML134).
Collapse
Affiliation(s)
- Thomas Troxler
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, 4057, Basel, Switzerland
| | - Dominik Feuerbach
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, 4057, Basel, Switzerland
| | - Xuechun Zhang
- ChemPartner, 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area, Shanghai, 201203, China
| | - Charles R Yang
- ShangPharma Innovation Inc., 280 Utah Avenue, South San Francisco, CA, 94080, USA
| | - Bharat Lagu
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Mark Perrone
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Tie-Lin Wang
- ChemPartner, 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area, Shanghai, 201203, China
| | - Karin Briner
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Mark G Bock
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Yves P Auberson
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, 4057, Basel, Switzerland
| |
Collapse
|
11
|
Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Histamine H 3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther 2019; 200:69-84. [PMID: 31028835 DOI: 10.1016/j.pharmthera.2019.04.007] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Accepted: 04/19/2019] [Indexed: 12/16/2022]
Abstract
Since the discovery of the histamine H3 receptor in 1983, tremendous advances in the pharmacological aspects of H3 receptor antagonists/inverse agonists have been accomplished in preclinical studies. At present, there are several drug candidates that reached clinical trial studies for various indications. However, entrance of these candidates to the pharmaceutical market is not free from challenges, and a variety of difficulties is engaged with their developmental process. In this review, the potential role of H3 receptors in the pathophysiology of various central nervous system, metabolic and allergic diseases is discussed. Thereafter, the current status for H3 receptor antagonists/inverse agonists in ongoing clinical trial studies is reviewed and obstacles in developing these agents are emphasized.
Collapse
Affiliation(s)
- Nakisa Ghamari
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Omid Zarei
- Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran; Neurosciences Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
| | - José-Antonio Arias-Montaño
- Departamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del IPN, Av. Instituto Politécnico Nacional 2508, Zacatenco, 07360 Ciudad de México, México
| | - David Reiner
- Heinrich Heine University Düsseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | - Siavoush Dastmalchi
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Holger Stark
- Heinrich Heine University Düsseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
| | - Maryam Hamzeh-Mivehroud
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
12
|
Xin J, Hu M, Liu Q, Zhang TT, Wang DM, Wu S. Design, synthesis, and biological evaluation of novel iso-flavones derivatives as H 3R antagonists. J Enzyme Inhib Med Chem 2018; 33:1545-1553. [PMID: 30293461 PMCID: PMC6179058 DOI: 10.1080/14756366.2018.1509212] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Histamine H3 receptor (H3R), a kind of G-protein coupled receptor (GPCR), is expressed mainly in the central nervous system (CNS) and plays a vital role in homoeostatic control. This study describes the design and synthesis of a series of novel H3R antagonists based on the iso-flavone scaffold. The results of the bioactivity evaluation show that four compounds (1c, 2c, 2h, and 2o) possess significant H3R inhibitory activities. Molecular docking indicates that a salt bridge, π-π T-shape interactions, and hydrophobic interaction all contribute to the interaction between compound 2h and H3R.
Collapse
Affiliation(s)
- Jian Xin
- a State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica , Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China
| | - Min Hu
- b School of Pharmacy , Inner Mongolia Medical University , Hohhot , China
| | - Qian Liu
- b School of Pharmacy , Inner Mongolia Medical University , Hohhot , China
| | - Tian Tai Zhang
- b School of Pharmacy , Inner Mongolia Medical University , Hohhot , China
| | - Dong Mei Wang
- b School of Pharmacy , Inner Mongolia Medical University , Hohhot , China
| | - Song Wu
- b School of Pharmacy , Inner Mongolia Medical University , Hohhot , China
| |
Collapse
|
13
|
Łażewska D, Kieć-Kononowicz K. Progress in the development of histamine H 3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat 2018; 28:175-196. [PMID: 29334795 DOI: 10.1080/13543776.2018.1424135] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Since years, ligands blocking histamine H3 receptor (H3R) activity (antagonists/inverse agonists) are interesting targets in the search for new cures for CNS disorders. Intensive works done by academic and pharmaceutical company researchers have led to many potent and selective H3R antagonists/inverse agonists. Some of them have reached to clinical trials. AREAS COVERED Patent applications from January 2013 to September 2017 and the most important topics connected with H3R field are analysed. Espacenet, Patentscope, Pubmed, GoogleScholar or Cochrane Library online databases were principially used to collect all the materials. EXPERT OPINION The research interest in histamine H3R field is still high although the number of patent applications has decreased during the past 4 years (around 20 publications). Complexity of histamine H3R biology e.g. many isoforms, constitutive activity, heteromerization with other receptors (dopamine D2, D1, adenosine A2A) and pharmacology make not easy realization and evaluation of therapeutic potential of anti-H3R ligands. First results from clinical trials have verified potential utility of histamine H3R antagonist/inverse agonists in some diseases. However, more studies are necessary for better understanding of an involvement of the histaminergic system in CNS-related disorders and helping more ligands approach to clinical trials and the market. Lists of abbreviations: hAChEI - human acetylcholinesterase inhibitor; hBuChEI - human butyrylcholinesterase inhibitor; hMAO - human monoamine oxidase; MAO - monoamine oxidase.
Collapse
Affiliation(s)
- Dorota Łażewska
- a Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Kraków , Poland
| | - Katarzyna Kieć-Kononowicz
- a Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Kraków , Poland
| |
Collapse
|
14
|
Zhang ZJ, Song J. An isothiourea-catalyzed asymmetric formal [4 + 2] cycloaddition of in situ generated azoalkenes with C1 ammonium enolates. Org Chem Front 2018. [DOI: 10.1039/c8qo00657a] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
An efficient isothiourea-catalyzed stereoselective formal [4 + 2] cycloaddition of α-chloro cyclic hydrazones with carboxylic acids has been developed.
Collapse
Affiliation(s)
- Zi-Jing Zhang
- Department of Chemistry
- University of Science and Technology of China
- Hefei 230026
- China
| | - Jin Song
- Department of Chemistry
- University of Science and Technology of China
- Hefei 230026
- China
| |
Collapse
|
15
|
Łażewska D, Kaleta M, Schwed JS, Karcz T, Mogilski S, Latacz G, Olejarz A, Siwek A, Kubacka M, Lubelska A, Honkisz E, Handzlik J, Filipek B, Stark H, Kieć-Kononowicz K. Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H 3 receptor ligands. Bioorg Med Chem 2017; 25:5341-5354. [PMID: 28797771 DOI: 10.1016/j.bmc.2017.07.058] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 07/25/2017] [Accepted: 07/28/2017] [Indexed: 12/31/2022]
Abstract
Novel biphenyloxy-alkyl derivatives of piperidine and azepane were synthesized and evaluated for their binding properties at the human histamine H3 receptor. Two series of compounds were obtained with a meta- and a para-biphenyl moiety. The alkyl chain spacer contained five and six carbon atoms. The highest affinity among all compounds was shown by 1-(6-(3-phenylphenoxy)hexyl)azepane (13) with a Ki value of 18nM. Two para-biphenyl derivatives, 1-(5-(4-phenylphenoxy)pentyl)piperidine (14; Ki=25nM) and 1-(5-(4-phenylphenoxy)pentyl)azepane (16; Ki=34nM), classified as antagonists in a cAMP accumulation assay (IC50=4 and 9nM, respectively), were studied in detail. Compounds 14 and 16 blocked RAMH-induced dipsogenia in rats (ED50 of 2.72mg/kg and 1.75mg/kg respectively), and showed high selectivity (hH4R vs hH3R>600-fold) and low toxicity (hERG inhibition: IC50>1.70µM; hepatotoxicity IC50>12.5µM; non-mutagenic up to 10µM). Furthermore, the metabolic stability was evaluated in vitro on human liver microsomes (HLMs) and/or rat liver microsomes (RLMs). Metabolites produced were analyzed and tentatively identified by UPLC-MS techniques. The results demonstrated easy hydroxylation of the biphenyl ring.
Collapse
Affiliation(s)
- Dorota Łażewska
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland.
| | - Maria Kaleta
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - J Stephan Schwed
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany
| | - Tadeusz Karcz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Szczepan Mogilski
- Department of Pharmacodynamic, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Gniewomir Latacz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Agnieszka Olejarz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Agata Siwek
- Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Monika Kubacka
- Department of Pharmacodynamic, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Annamaria Lubelska
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Ewelina Honkisz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Filipek
- Department of Pharmacodynamic, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany
| | - Katarzyna Kieć-Kononowicz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Kraków, Poland.
| |
Collapse
|
16
|
Zhou T, Yang L, Liang L, Liu H, Zhu Y, Shui M, Yuan L, Xu F, Niu Y, Wang C, Xu P. Rational Design of a Near-Infrared Fluorescent Probe Based on a Pyridazinone Scaffold. European J Org Chem 2017. [DOI: 10.1002/ejoc.201700355] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- Tongliang Zhou
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Lingfei Yang
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Lei Liang
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Hui Liu
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Yuanjun Zhu
- Department of Molecular and Cellular Pharmacology; School of Pharmaceutical Sciences; Peking University; Beijing China
| | - Mengyang Shui
- Department of Molecular and Cellular Pharmacology; School of Pharmaceutical Sciences; Peking University; Beijing China
| | - Lan Yuan
- Medical and Healthy Analysis Center; Peking University; Beijing China
| | - Fengrong Xu
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Yan Niu
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Chao Wang
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| | - Ping Xu
- Department of Medicinal Chemistry; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China
| |
Collapse
|
17
|
|
18
|
Akhtar W, Shaquiquzzaman M, Akhter M, Verma G, Khan MF, Alam MM. The therapeutic journey of pyridazinone. Eur J Med Chem 2016; 123:256-281. [DOI: 10.1016/j.ejmech.2016.07.061] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 07/20/2016] [Accepted: 07/24/2016] [Indexed: 11/17/2022]
|
19
|
Sadek B, Khan N, Darras FH, Pockes S, Decker M. The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats. Physiol Behav 2016; 165:383-91. [DOI: 10.1016/j.physbeh.2016.08.022] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2016] [Revised: 08/23/2016] [Accepted: 08/23/2016] [Indexed: 12/31/2022]
|
20
|
Spiegelstein O, Stevens J, Van Gerven J, Nathan PJ, Maynard JP, Mayleben DW, Hellriegel E, Yang R. Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. J Psychopharmacol 2016; 30:983-93. [PMID: 27222271 DOI: 10.1177/0269881116645301] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
CEP-26401 is a novel orally active, brain-penetrant, high-affinity histamine H3 receptor (H3R) antagonist, with potential therapeutic utility in cognition enhancement. Two randomized, double-blind, placebo-controlled dose escalation studies with single (0.02 to 5 mg) or multiple administration (0.02 to 0.5 mg once daily) of CEP-26401 were conducted in healthy subjects. Plasma and urine samples were collected to investigate CEP-26401 pharmacokinetics. Pharmacodynamic endpoints included a subset of tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB) and nocturnal polysomnography. Population pharmacokinetic-pharmacodynamic modeling was conducted on one CANTAB and one polysomnography parameter of interest. CEP-26401 was slowly absorbed (median tmax range 3-6 hours) and the mean terminal elimination half-life ranged from 24-60 hours. Steady-state plasma concentrations were achieved within six days of dosing. CEP-26401 exhibits dose- and time-independent pharmacokinetics, and renal excretion is a major elimination pathway. CEP-26401 had a dose-dependent negative effect on sleep, with some positive effects on certain CANTAB cognitive parameters seen at lower concentrations. The derived three compartment population pharmacokinetic model, with first-order absorption and elimination, accurately described the available pharmacokinetic data. CEP-26401 was generally well tolerated up to 0.5 mg/day with most common treatment related adverse events being headache and insomnia. Further clinical studies are required to establish the potential of low-dose CEP-26401 in cognition enhancement.
Collapse
Affiliation(s)
| | | | | | - Pradeep J Nathan
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | | | | | - Edward Hellriegel
- Research and Development Teva Pharmaceuticals, West Chester, PA, USA
| | - Ronghua Yang
- Research and Development Teva Pharmaceuticals, West Chester, PA, USA
| |
Collapse
|
21
|
Yoneyama H, Yamamoto D, Yamatodani A, Harusawa S. Efficient Approaches to <i>S</i>-alkyl-<i>N</i>-alkylisothioureas and Application to Novel Histamine H<sub>3</sub>R Antagonists. YAKUGAKU ZASSHI 2016; 136:1217-32. [DOI: 10.1248/yakushi.16-00023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Hiroki Yoneyama
- Laboratory of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences
| | | | | | - Shinya Harusawa
- Laboratory of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
22
|
Yang L, Zhu Y, Shui M, Zhou T, Cai Y, Wang W, Xu F, Niu Y, Wang C, Zhang JL, Xu P, Yuan L, Liang L. Rational Design of Fluorescent Phthalazinone Derivatives for One- and Two-Photon Imaging. Chemistry 2016; 22:12363-70. [DOI: 10.1002/chem.201601499] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Indexed: 12/13/2022]
Affiliation(s)
- Lingfei Yang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
- Medical and Healthy Analysis Center; Peking University; Beijing P. R. China
| | - Yuanjun Zhu
- Department of Molecular and Cellular Pharmacology; School of Pharmaceutical Sciences; Peking University; Beijing P. R. China
| | - Mengyang Shui
- Department of Molecular and Cellular Pharmacology; School of Pharmaceutical Sciences; Peking University; Beijing P. R. China
| | - Tongliang Zhou
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Yuanbo Cai
- Beijing National Laboratory for Molecular Science; State Key Laboratory of Rare Earth Materials Chemistry and Applications; College of Chemistry and Molecular Engineering; Peking University; Beijing P. R.China
| | - Wei Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Fengrong Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Yan Niu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Chao Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Jun-Long Zhang
- Beijing National Laboratory for Molecular Science; State Key Laboratory of Rare Earth Materials Chemistry and Applications; College of Chemistry and Molecular Engineering; Peking University; Beijing P. R.China
| | - Ping Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| | - Lan Yuan
- Medical and Healthy Analysis Center; Peking University; Beijing P. R. China
| | - Lei Liang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing P. R. China
| |
Collapse
|
23
|
Sadek B, Saad A, Sadeq A, Jalal F, Stark H. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res 2016; 312:415-30. [PMID: 27363923 DOI: 10.1016/j.bbr.2016.06.051] [Citation(s) in RCA: 111] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 06/22/2016] [Accepted: 06/26/2016] [Indexed: 01/27/2023]
Abstract
The potential contributions of the brain histaminergic system in neurodegenerative diseases, and the possiblity of histamine-targeting treatments is attracting considerable interests. The histamine H3 receptor (H3R) is expressed mainly in the central nervous system, and is, consequently, an attractive pharmacological target. Although recently described clinical trials have been disappointing in attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCH), numerous H3R antagonists, including pitolisant, demonstrate potential in the treatment of narcolepsy, excessive daytime sleepiness associated with cognitive impairment, epilepsy, and Alzheimer's disease (AD). This review focuses on the recent preclinical as well as clinical results that support the relevance of H3R antagonists for the treatment of cognitive symptoms in neuropsychiatric diseases, namely AD, epilepsy and SCH. The review summarizes the role of histaminergic neurotransmission with focus on these brain disorders, as well as the effects of numerous H3R antagonists on animal models and humans.
Collapse
Affiliation(s)
- Bassem Sadek
- Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
| | - Ali Saad
- Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates
| | - Adel Sadeq
- College of Pharmacy, Al Ain University of Science and Technology, Al Ain, United Arab Emirates
| | - Fakhreya Jalal
- Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Universitaetsstr. 1, 40225 Düsseldorf, Germany
| |
Collapse
|
24
|
Yang L, Wang W, Sun Q, Xu F, Niu Y, Wang C, Liang L, Xu P. Development of novel proteasome inhibitors based on phthalazinone scaffold. Bioorg Med Chem Lett 2016; 26:2801-2805. [PMID: 27158142 DOI: 10.1016/j.bmcl.2016.04.067] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 04/11/2016] [Accepted: 04/23/2016] [Indexed: 11/18/2022]
Abstract
In this study we designed a series of proteasome inhibitors using pyridazinone as initial scaffold, and extended the structure with rational design by computer aided drug design (CADD). Two different synthetic routes were explored and the biological evaluation of the phthalazinone derivatives was investigated. Most importantly, electron positive triphenylphosphine group was first introduced in the structure of proteasome inhibitors and potent inhibition was achieved. As 6c was the most potent inhibitor of proteasome, we examined the structure-activity relationship (SAR) of 6c analogs.
Collapse
Affiliation(s)
- Lingfei Yang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Wei Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Qi Sun
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Fengrong Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Yan Niu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Chao Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Lei Liang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
| | - Ping Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| |
Collapse
|
25
|
Pontiki E, Hadjipavlou-Litina D. QSAR models on H4 receptor antagonists associated with inflammation and anaphylaxis. J Biomol Struct Dyn 2016; 35:968-1005. [DOI: 10.1080/07391102.2016.1166986] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Eleni Pontiki
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki , Thessaloniki 54124, Greece
| | - Dimitra Hadjipavlou-Litina
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki , Thessaloniki 54124, Greece
| |
Collapse
|
26
|
Sadek B, Stark H. Cherry-picked ligands at histamine receptor subtypes. Neuropharmacology 2015; 106:56-73. [PMID: 26581501 DOI: 10.1016/j.neuropharm.2015.11.005] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Revised: 11/05/2015] [Accepted: 11/06/2015] [Indexed: 12/17/2022]
Abstract
Histamine, a biogenic amine, is considered as a principle mediator of multiple physiological effects through binding to its H1, H2, H3, and H4 receptors (H1-H4Rs). Currently, the HRs have gained attention as important targets for the treatment of several diseases and disorders ranging from allergy to Alzheimer's disease and immune deficiency. Accordingly, medicinal chemistry studies exploring histamine-like molecules and their physicochemical properties by binding and interacting with the four HRs has led to the development of a diversity of agonists and antagonists that display selectivity for each HR subtype. An overview on H1-R4Rs and developed ligands representing some key steps in development is provided here combined with a short description of structure-activity relationships for each class. Main chemical diversities, pharmacophores, and pharmacological profiles of most innovative H1-H4R agonists and antagonists are highlighted. Therefore, this overview should support the rational choice for the optimal ligand selection based on affinity, selectivity and efficacy data in biochemical and pharmacological studies. This article is part of the Special Issue entitled 'Histamine Receptors'.
Collapse
Affiliation(s)
- Bassem Sadek
- Department of Pharmacology and Therapeutics, College of Medicine & Health Sciences, United Arab Emirates University, PO Box 17666, Al Ain, United Arab Emirates.
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Universitaetsstr. 1, 40225 Düsseldorf, Germany
| |
Collapse
|
27
|
Hudkins RL, Gruner JA, Raddatz R, Mathiasen JR, Aimone LD, Marino MJ, Bacon ER, Williams M, Ator MA. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist. Neuropharmacology 2015; 106:37-45. [PMID: 26400408 DOI: 10.1016/j.neuropharm.2015.09.025] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Revised: 09/09/2015] [Accepted: 09/17/2015] [Indexed: 10/23/2022]
Abstract
CEP-32215 is a new, potent, selective, and orally bioavailable inverse agonist of the histamine H3 receptor (H3R) with drug-like properties. High affinity in human (hH3R Ki = 2.0 ± 0.2 nM) and rat (rH3R Ki = 3.6 ± 0.7 nM) H3R radioligand binding assays was demonstrated. Potent functional antagonism (Kb = 0.3 ± 0.1 nM) and inverse agonism (EC50 = 0.6 ± 0.2 nM) were demonstrated in [(35)S]guanosine 5(')-O-(γ-thio)-triphosphate binding assays. Oral bioavailability and dose-related exposure was consistent among rat, dog, and monkey. After oral dosing, occupancy of H3R by CEP-32215 was estimated by the inhibition of ex vivo binding in rat cortical slices (ED50 = 0.1 mg/kg p.o.). Functional antagonism in brain was demonstrated by the inhibition of R-α-methylhistamine-induced drinking in the rat dipsogenia model (ED50 = 0.92 mg/kg). CEP-32215 significantly increased wake duration in the rat EEG model at 3-30 mg/kg p.o. Increased motor activity, sleep rebound or undesirable events (such as spike wave or seizure activity) was not observed following doses up to 100 mg/kg p.o., indicating an acceptable therapeutic index. CEP-32215 may have potential utility in the treatment of a variety of sleep disorders. This article is part of the Special Issue entitled 'Histamine Receptors'.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | - John A Gruner
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Rita Raddatz
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Joanne R Mathiasen
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Lisa D Aimone
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Michael J Marino
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Edward R Bacon
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Michael Williams
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Mark A Ator
- Discovery and Product Development, Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA
| |
Collapse
|
28
|
Hudkins RL, Becknell NC, Lyons JA, Aimone LD, Olsen M, Haltiwanger RC, Mathiasen JR, Raddatz R, Gruner JA. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity. Eur J Med Chem 2015; 95:349-56. [DOI: 10.1016/j.ejmech.2015.03.054] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 03/21/2015] [Accepted: 03/23/2015] [Indexed: 12/25/2022]
|
29
|
Wang W, Liang L, Xu F, Huang W, Niu Y, Sun Q, Xu P. Ruthenium-Catalyzed Switchable N-H/C-H Alkenylation of 6-Phenyl(dihydro)pyridazinones with Alkynes. European J Org Chem 2014. [DOI: 10.1002/ejoc.201402986] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
30
|
Hudkins RL, Josef KA, Becknell NC, Aimone LD, Lyons JA, Mathiasen JR, Gruner JA, Raddatz R. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity. Bioorg Med Chem Lett 2014; 24:1303-6. [PMID: 24513042 DOI: 10.1016/j.bmcl.2014.01.061] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Revised: 01/16/2014] [Accepted: 01/21/2014] [Indexed: 02/01/2023]
Abstract
A series of fused cyclopropyl-4,5-dihydropyridazin-3-one (3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one) phenoxypiperidine analogs was designed and synthesized, leading to the identification of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a) as a second-generation pyridazin-3-one H3R antagonist. Compound R,S-4a was a potent H3R functional antagonist in vivo in the rat dipsogenia model, demonstrated potent wake activity in the rat EEG/EMG model, and enhanced short-term memory in the rat social recognition memory model at doses as low as 0.03-0.3 mg/kg po.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | - Kurt A Josef
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Nadine C Becknell
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Lisa D Aimone
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Jacquelyn A Lyons
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Joanne R Mathiasen
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - John A Gruner
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Rita Raddatz
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| |
Collapse
|
31
|
Bao X, Jin Y, Liu X, Liao H, Zhang L, Pang T. Synthesis and biological evaluation of XB-1 analogues as novel histamine H3 receptor antagonists and neuroprotective agents. RSC Adv 2014. [DOI: 10.1039/c3ra46392c] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
32
|
Harusawa S, Sawada K, Magata T, Yoneyama H, Araki L, Usami Y, Hatano K, Yamamoto K, Yamamoto D, Yamatodani A. Synthesis and evaluation of N-alkyl-S-[3-(piperidin-1-yl)propyl]isothioureas: High affinity and human/rat species-selective histamine H3 receptor antagonists. Bioorg Med Chem Lett 2013; 23:6415-20. [DOI: 10.1016/j.bmcl.2013.09.052] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 09/11/2013] [Accepted: 09/17/2013] [Indexed: 10/26/2022]
|
33
|
Łażewska D, Kieć-Kononowicz K. New developments around histamine H3receptor antagonists/inverse agonists: a patent review (2010 – present). Expert Opin Ther Pat 2013; 24:89-111. [DOI: 10.1517/13543776.2014.848197] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
34
|
Tang L, Zhao L, Hong L, Yang F, Sheng R, Chen J, Shi Y, Zhou N, Hu Y. Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers. Bioorg Med Chem 2013; 21:5936-44. [DOI: 10.1016/j.bmc.2013.07.051] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Revised: 07/29/2013] [Accepted: 07/30/2013] [Indexed: 10/26/2022]
|
35
|
Liang L, Wang W, Wu J, Xu F, Niu Y, Xu B, Xu P. Rational Design, Green Synthesis, and Initial Evaluation of a Series of Full-Color Tunable Fluorescent Dyes Enabled by the Copper-Catalyzed N-Arylation of 6-Phenyl Pyridazinones and Their Application in Cell Imaging. Chemistry 2013; 19:13774-82. [DOI: 10.1002/chem.201302495] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2013] [Indexed: 11/09/2022]
|
36
|
Levoin N, Labeeuw O, Krief S, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M. Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists. Bioorg Med Chem 2013; 21:4526-9. [DOI: 10.1016/j.bmc.2013.05.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Revised: 05/16/2013] [Accepted: 05/21/2013] [Indexed: 12/28/2022]
|
37
|
Liang L, Yang G, Xu F, Niu Y, Sun Q, Xu P. Copper-Catalyzed Aerobic Dehydrogenation of C-C to C=C Bonds in the Synthesis of Pyridazinones. European J Org Chem 2013. [DOI: 10.1002/ejoc.201300640] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
38
|
Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, Pruniaux MP, Schwink L, Sanchez JA, Stengelin S, Tang L, Winkler I, Hendrix JA, George PG. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I). Bioorg Med Chem Lett 2013; 23:3416-20. [PMID: 23591110 DOI: 10.1016/j.bmcl.2013.03.080] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Revised: 03/18/2013] [Accepted: 03/20/2013] [Indexed: 11/28/2022]
Abstract
A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists. The SAR was explored and the data obtained set up the starting point and foundation for further optimization. The most potent tool compounds, as exemplified by compounds 2l, 5b, 5d, and 5e, displayed antagonism potencies in the subnanomolar range in in vitro human-H3R FLIPR assays and rhesus monkey H3R binding assays.
Collapse
Affiliation(s)
- Zhongli Gao
- LGCR SMRPD Chemical Research, Sanofi US, 153-1-122, 153 2nd Ave, Waltham, MA 02451, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, Pruniaux MP, Schwink L, Sanchez JA, Stengelin S, Tang L, Winkler I, Hendrix JA, George PG. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part II). Bioorg Med Chem Lett 2013; 23:3421-6. [DOI: 10.1016/j.bmcl.2013.03.081] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Revised: 03/18/2013] [Accepted: 03/20/2013] [Indexed: 01/06/2023]
|
40
|
Liang L, Wang W, Xu F, Niu Y, Sun Q, Xu P. Relay catalysis by a multifunctional Cu catalyst in a tandem dehydro-/dehalogenation sequence along with N-arylation. Org Lett 2013; 15:2770-3. [PMID: 23672594 DOI: 10.1021/ol401105x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
A Cu-catalyzed tandem dehydrogenation/dehalogenation sequential reaction along with N-arylation has been developed for the synthesis of pyridazinone derivatives in an aerobic and aqueous environment. To achieve the transformation of three chemical bonds in a one-pot reaction, a multifunctional copper catalyst was used which afforded excellent activity, high selectivity, and recyclability. The catalytic system consists of a water-soluble Cusalen complex and Na2CO3 in neat water and an air atmosphere.
Collapse
Affiliation(s)
- Lei Liang
- State Key Laboratory of Natural and Biomimetic Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191 China
| | | | | | | | | | | |
Collapse
|
41
|
Liang L, Yang G, Wang W, Xu F, Niu Y, Sun Q, Xu P. A Copper-Catalyzed Aerobic Cascade Dehydrogenative- Dehalogenative Reaction. Adv Synth Catal 2013. [DOI: 10.1002/adsc.201300026] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
Wang Y, Przyuski K, Roemmele RC, Hudkins RL, Bakale RP. Development and Scale-Up of an Optimized Route to the Pyridazin-3-one Histamine H3 Receptor Antagonist CEP-32215. Org Process Res Dev 2013. [DOI: 10.1021/op400039d] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yi Wang
- Worldwide
Process
Research and Development, Teva Pharmaceuticals, 383 Phoenixville Pike, Malvern, Pennsylvania 19355, United States
| | - Katrin Przyuski
- Worldwide
Process
Research and Development, Teva Pharmaceuticals, 383 Phoenixville Pike, Malvern, Pennsylvania 19355, United States
| | - Renee C. Roemmele
- Worldwide
Process
Research and Development, Teva Pharmaceuticals, 383 Phoenixville Pike, Malvern, Pennsylvania 19355, United States
| | - Robert L. Hudkins
- Discovery Research, Teva Pharmaceuticals, 145 Brandywine
Parkway, West Chester, Pennsylvania 19380, United States
| | - Roger P. Bakale
- Worldwide
Process
Research and Development, Teva Pharmaceuticals, 383 Phoenixville Pike, Malvern, Pennsylvania 19355, United States
| |
Collapse
|
43
|
Dunn D, Raddatz R, Ator MA, Bacon ER, Chatterjee S. From an Atypical Wake-promoting Agent to Potent Histamine-3 Receptor Inverse Agonists. Chem Biol Drug Des 2013. [DOI: 10.1111/cbdd.12094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Functionalization of the pyridazin-3(2H)-one ring via palladium-catalysed aminocarbonylation. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.07.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
45
|
Josef KA, Aimone LD, Lyons J, Raddatz R, Hudkins RL. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists. Bioorg Med Chem Lett 2012; 22:4198-202. [DOI: 10.1016/j.bmcl.2012.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 03/23/2012] [Accepted: 04/02/2012] [Indexed: 10/28/2022]
|
46
|
Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists. Bioorg Med Chem 2012; 20:3880-6. [DOI: 10.1016/j.bmc.2012.04.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 04/04/2012] [Accepted: 04/10/2012] [Indexed: 12/12/2022]
|
47
|
Zulli AL, Aimone LD, Mathiasen JR, Gruner JA, Raddatz R, Bacon ER, Hudkins RL. Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists. Bioorg Med Chem Lett 2012; 22:2807-10. [DOI: 10.1016/j.bmcl.2012.02.081] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 02/22/2012] [Accepted: 02/23/2012] [Indexed: 10/28/2022]
|
48
|
Dandu RR, Lyons JA, Raddatz R, Huang Z, Aimone LD, Hudkins RL. Synthesis and evaluation of a new series of 1′-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4′-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists. Bioorg Med Chem Lett 2012; 22:2151-3. [DOI: 10.1016/j.bmcl.2012.01.139] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Revised: 01/30/2012] [Accepted: 01/31/2012] [Indexed: 11/24/2022]
|
49
|
Zhou D, Gross JL, Adedoyin AB, Aschmies SB, Brennan J, Bowlby M, Di L, Kubek K, Platt BJ, Wang Z, Zhang G, Brandon N, Comery TA, Robichaud AJ. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists. J Med Chem 2012; 55:2452-68. [DOI: 10.1021/jm300011d] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Dahui Zhou
- Pfizer Global Research and Development, 445 Eastern Point Road, Groton,
Connecticut 06340, United States
| | - Jonathan L. Gross
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Adedayo B. Adedoyin
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Suzan B. Aschmies
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Julie Brennan
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Mark Bowlby
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Li Di
- Pfizer Global Research and Development, 445 Eastern Point Road, Groton,
Connecticut 06340, United States
| | - Katie Kubek
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Brian J. Platt
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Zheng Wang
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| | - Guoming Zhang
- Pfizer Global Research and Development, 445 Eastern Point Road, Groton,
Connecticut 06340, United States
| | - Nicholas Brandon
- Pfizer Global Research and Development, 445 Eastern Point Road, Groton,
Connecticut 06340, United States
| | - Thomas A. Comery
- Pfizer Global Research and Development, 445 Eastern Point Road, Groton,
Connecticut 06340, United States
| | - Albert J. Robichaud
- Pfizer Global Research and Development, CN 8000, Princeton, New Jersey
08543, United States
| |
Collapse
|
50
|
Sundar BG, Bailey TR, Dunn D, Hostetler GA, Chatterjee S, Bacon ER, Yue C, Schweizer D, Aimone LD, Gruner JA, Lyons J, Raddatz R, Lesur B. Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity. Bioorg Med Chem Lett 2012; 22:1546-9. [DOI: 10.1016/j.bmcl.2012.01.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 01/02/2012] [Accepted: 01/03/2012] [Indexed: 11/28/2022]
|